VMMC
ADAP

V.M. Manning & Co’s Adaptimmune Therapeutics ADAP Stock Holding History

V.M. Manning & Co’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-22,200
Closed -$1.39K – 53
2025
Q2 		$1.39K Buy
+22,200
New +$5.92K ﹤0.01% 47

Other funds holding ADAP

LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
EF
Empirical Finance Havertown, Pennsylvania $2.13B AUM 29.56% 1-Year Est. Return
BRWA
B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return

V.M. Manning & Co's ADAP Position: Q3 2025 in Review

V.M. Manning & Co sold out of Adaptimmune Therapeutics (ADAP) in Q3 2025, closing a stake of 22,200 shares — an estimated $1.39K sold.

V.M. Manning & Co first reported a position in ADAP in Q2 2025 and held it in 1 quarter. The position peaked at $1.39K in Q2 2025. 55 funds tracked by Wall St. Rank hold ADAP as of Q3 2025.

  • V.M. Manning & Co reported no remaining Adaptimmune Therapeutics position as of Q3 2025 after selling out during the quarter.
  • V.M. Manning & Co sold 22,200 Adaptimmune Therapeutics shares in Q3 2025, an estimated $1.39K.
  • V.M. Manning & Co first reported a position in Adaptimmune Therapeutics in Q2 2025 and held it in 1 quarter.
  • V.M. Manning & Co's Adaptimmune Therapeutics position peaked at $1.39K in Q2 2025.
  • 55 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q3 2025.

Based on V.M. Manning & Co's 13F filing for Q3 2025, filed 16 Oct 2025.